Showing 2361-2370 of 3039 results for "".
- Bausch + Lomb Completes Acquisition of Xiidrahttps://modernod.com/news/bausch-lomb-completes-acquisition-of-xiidra/2481861/Bausch + Lomb announced it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution 5%), a non-steroid eye drop approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. In June, Bausch + Lomb&
- Orbis International Teams Up with the Alcon Foundation and OMEGA to Improve Eye Care in Zambiahttps://modernod.com/news/orbis-international-teams-up-with-the-alcon-foundation-and-omega-to-improve-eye-care-in-zambia/2481851/Global eye care nonprofit Orbis International is kicking off a surgical training program in Zambia&nb
- BostonSight Receives MMAP Grant to Expand and Automate Scleral Lens Manufacturinghttps://modernod.com/news/bostonsight-receives-mmap-grant-to-expand-and-automate-scleral-lens-manufacturing/2481848/BostonSight, a nonprofit healthcare organization that advances the treatment of diseased and damaged corneas and dry eye, announced it has received a $200,000 manufacturing grant from the Massachusetts Manufacturing Accelerate Program (MMAP) to advance its scleral lens manufacturing capabili
- Bausch + Lomb Launches Lumify Eye Illuminations in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-eye-illuminations-in-the-united-states/2481846/Bausch + Lomb announced the US launch of Lumify Eye Illuminations, a new line of hypoallergenic specialty eye care products developed to cleanse, nourish and brighten the sensitive eye area. “Many products contain chemicals or preservatives that can irritate the del
- Bausch + Lomb Launches Dry Eye Drug Miebo in the United Stateshttps://modernod.com/news/bausch-lomb-launches-dry-eye-drug-miebo-in-the-united-states/2481826/Bausch + Lomb announced the US commercial launch of Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). In May, Bausch + Lomb and Novaliq received FDA for Miebo as the first and only FDA-approved
- Ace Vision Group to Present Nine New Sets of Scientific Data Focused on Laser Scleral Microporation at the ESCRS Annual Meetinghttps://modernod.com/news/ace-vision-group-to-present-nine-new-sets-of-scientific-data-focused-on-laser-scleral-microporation-at-the-escrs-annual-meeting/2481820/Ace Vision Group (AVG) announced it will present nine sets of research on the effectiveness of Laser Scleral Microporation (LSM) at the annual congress of the European Society of Cataract and Refractive Surgeons (ESCRS). LSM is an ultra-minimally invasive procedure with a nov
- Myra Vision Announces First-in-Human Use of its Calibreye Glaucoma Drainage Devicehttps://modernod.com/news/myra-vision-announces-first-in-human-use-of-its-calibreye-glaucoma-drainage-device/2481816/Myra Vision announced it has initiated its first-in-human clinical study of the Calibreye System, a glaucoma drainage device with titratable outflow control designed to achieve optimal reduction of IOP for moderate to severe glaucoma patients. The prospective, non-randomized open-label
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- Atsena Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-announces-first-patient-dosed-in-phase-12-clinical-trial-of-atsn-201-for-the-treatment-of-x-linked-retinoschisis/2481796/Atsena Therapeutics announced the first patient has been dosed in the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 uses AAV.SPR, the company’s novel spreading c
- Short-Term Use of Immunosuppressants for Ocular Inflammatory Diseases Not Linked to Cancer Riskhttps://modernod.com/news/short-term-use-of-immunosuppressants-for-ocular-inflammatory-diseases-not-linked-to-cancer-risk/2481793/Relatively short-term use of immunosuppressant medications to control noninfectious ocular inflammatory diseases was not associated with an increased risk of later developing cancer, according to new research led by scientists at the University of Pittsburgh and Mass Eye and Ear, a member of